Enterprise Value
3.046B
Cash
437.1M
Avg Qtr Burn
-27.87M
Short % of Float
23.27%
Insider Ownership
17.14%
Institutional Own.
70.65%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AUVELITY [AXS-05] (NMDA receptor antagonist & sigma-1 agonist) Details Major depressive disorder, Mental health | Approved Quarterly sales | |
Sunosi® (solriamfetol) Details Mental health, Excessive daytime sleepiness | Approved Quarterly sales | |
NDA Resubmission | ||
AXS-14 (esreboxetine) (NE reuptake inhibitor) Details Pain, Muscle pain, Fibromyalgia | NDA Submission | |
Solriamfetol Details Attention deficit hyperactivity disorder | Phase 3 Data readout | |
AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details Alzheimer's disease | Phase 3 Data readout | |
AXS-12 (reboxetine) (NE reuptake inhibitor) Details Narcolepsy Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Solriamfetol Details Shift work disorder | Phase 3 Initiation | |
Solriamfetol Details Binge eating disorder | Phase 3 Initiation | |
AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details Smoking cessation | Phase 2/3 Initiation |